# A Extension Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine

> **NCT04967742** · PHASE1 · COMPLETED · sponsor: **United Biomedical Inc., Asia** · enrollment: 50 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** UB-612

## Key facts

- **NCT ID:** NCT04967742
- **Lead sponsor:** United Biomedical Inc., Asia
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-05
- **Primary completion:** 2021-08-22
- **Final completion:** 2021-10-31
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2022-08-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04967742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04967742, "A Extension Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT04967742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*